{"doi":"10.1111/ajad.13518","title":"Extended‐release buprenorphine in pregnancy","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Objectives</jats:title><jats:p>The relative safety and efficacy of monthly extended‐release buprenorphine (XR‐BUP) has not been fully evaluated in pregnant persons.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Case report of two pregnant individuals receiving XR‐BUP while pregnant.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Both patients had positive experiences and healthy infants.</jats:p></jats:sec><jats:sec><jats:title>Discussion and Conclusions</jats:title><jats:p>Sparse data regarding the use of XR‐BUP in pregnant patients limits shared decision‐making. Additional evidence will support the growing population of pregnant patients exposed to XR‐BUP.</jats:p></jats:sec><jats:sec><jats:title>Scientific Significance</jats:title><jats:p>Positive patient experiences using XR‐BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR‐BUP during pregnancy.</jats:p></jats:sec>","journal":"The American Journal on Addictions","year":2024,"id":644992,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1679224,"name":"Ese Aghenta","orcid":null,"position":1,"is_corresponding":false},{"id":1679225,"name":"Cresta Jones","orcid":null,"position":2,"is_corresponding":false},{"id":331552,"name":"Sheila Specker","orcid":"0000-0002-3362-6566","position":3,"is_corresponding":false},{"id":1679223,"name":"Alexander Hubbell","orcid":"0009-0002-2031-5192","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Extended‐release buprenorphine in pregnancy","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Objectives</jats:title><jats:p>The relative safety and efficacy of monthly extended‐release buprenorphine (XR‐BUP) has not been fully evaluated in pregnant persons.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Case report of two pregnant individuals receiving XR‐BUP while pregnant.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Both patients had positive experiences and healthy infants.</jats:p></jats:sec><jats:sec><jats:title>Discussion and Conclusions</jats:title><jats:p>Sparse data regarding the use of XR‐BUP in pregnant patients limits shared decision‐making. Additional evidence will support the growing population of pregnant patients exposed to XR‐BUP.</jats:p></jats:sec><jats:sec><jats:title>Scientific Significance</jats:title><jats:p>Positive patient experiences using XR‐BUP during pregnancy have been previously unreported. This report will contribute to discussions of risks and benefits for future patients using XR‐BUP during pregnancy.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38264845","pmcid":null,"openalex_id":"https://openalex.org/W4391173623","authors":[],"funders":[],"total_grants":0,"fwci":8.2318,"citation_percentile":0.97071579,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":5},{"year":2026,"count":3}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajad.13518","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajad.13518","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajad.13518","host_type":"publisher"},{"url":"https://doi.org/10.1111/ajad.13518","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38264845","host_type":"repository"}],"fields_of_study":["Prenatal Substance Exposure Effects","Maternal Mental Health During Pregnancy and Postpartum","Opioid Use Disorder Treatment"],"mesh_terms":["Buprenorphine","Delayed-Action Preparations","Female","Humans","Naltrexone","Narcotic Antagonists","Opioid-Related Disorders","Pregnancy"],"keywords":["Buprenorphine","Pregnancy","Obstetrics","Medicine","Anesthesia","Opioid","Internal medicine","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T02:35:30.554154Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}